Interestingly, a recent study reported that the GLP-1R agonist liraglutide ameliorates NAFLD in diabetic mice via the IRS2/PI3K/AKT signaling pathways [74]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.